Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Assets (2017 - 2025)

Crinetics Pharmaceuticals has reported Assets over the past 9 years, most recently at $1.1 billion for Q4 2025.

  • For Q4 2025, Assets fell 21.49% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $1.1 billion, down 21.49%, while the annual FY2025 figure was $1.1 billion, 21.49% down from the prior year.
  • Assets for Q4 2025 was $1.1 billion at Crinetics Pharmaceuticals, down from $1.2 billion in the prior quarter.
  • Over five years, Assets peaked at $1.4 billion in Q4 2024 and troughed at $163.5 million in Q1 2021.
  • A 5-year average of $678.8 million and a median of $528.5 million in 2022 define the central range for Assets.
  • Biggest five-year swings in Assets: tumbled 30.46% in 2023 and later skyrocketed 219.02% in 2024.
  • Year by year, Assets stood at $351.0 million in 2021, then rose by 0.33% to $352.2 million in 2022, then soared by 80.41% to $635.4 million in 2023, then soared by 125.79% to $1.4 billion in 2024, then decreased by 21.49% to $1.1 billion in 2025.
  • Business Quant data shows Assets for CRNX at $1.1 billion in Q4 2025, $1.2 billion in Q3 2025, and $1.3 billion in Q2 2025.